Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a…
By L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, S. Tjulandin, M. Zambetti, F. Vázquez, Mikhail Byakhow, M. Lichinitser and 10 more. The Lancet, 2010
1,220 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/bd1e280060ab3ed7beec785d9e81edf612a15e39
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
In Pathology and Forensic Medicine
Citations in the corpus
- The tumor microenvironment. (2012, methodology): “It was tested in the NOAH trial and proved to be a beneficial adjunct to chemotherapy in women with Her2/neu positive breast cancer [58].”
- Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis (2011, result): “The high local control after SRS and the improved control of extracranial disease reported with the combination of cytotoxic and targeted agents [37-41] may, at least in part, explain these results.”
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, background): “Targeted therapy in the neoadjuvant setting The NOAH study [62] showed clear improvement in breast pathological complete remission (bpCR) rate and event-free survival at 3 years with neoadjuvant trastuzumab for patients with HER2-positive disease.”
- Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. (2011, background): “The smaller Neoadjuvant Herceptin (NOAH) study evaluated the clinical benefit of chemotherapy alone (ie, doxorubicin plus paclitaxel followed by paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil) or with trastuzumab starting concurrently with doxorubicin in patients with HER2-p”
- ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “Achievement of a pathological complete response (path CR) in the breast and axillary lymph nodes after neoadjuvant trastuzumab or chemotherapy has been associated with improved long-term outcome (Gianni et al., 2010; Liedtke et al., 2008).”